Cargando…

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51

Acute myeloid leukemia (AML) remains a challenging disease to treat and urgently requires new therapies to improve its treatment outcome. In this study, we investigated the molecular mechanisms underlying the cooperative antileukemic activities of panobinostat and cytarabine or daunorubicin (DNR) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Chengzhi, Drenberg, Christina, Edwards, Holly, Caldwell, J. Timothy, Chen, Wei, Inaba, Hiroto, Xu, Xuelian, Buck, Steven A., Taub, Jeffrey W., Baker, Sharyn D., Ge, Yubin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823972/ https://www.ncbi.nlm.nih.gov/pubmed/24244429 http://dx.doi.org/10.1371/journal.pone.0079106

Ejemplares similares

Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells
por: Zhao, Jianyun, et al.
Publicado: (2016)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
por: Raut, Lalit S.
Publicado: (2015)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
por: Libura, Marta, et al.
Publicado: (2021)

Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells
por: Wang, Guan, et al.
Publicado: (2013)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Cytarabine/daunorubicin: Coronavirus disease-2019 pneumonia: case report
Publicado: (2021)

Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
por: Xu, Xuelian, et al.
Publicado: (2011)

RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation
por: Badie, Sophie, et al.
Publicado: (2009)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis
por: Tomic, Barbara, et al.
Publicado: (2022)

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Cytarabine/daunorubicin: Infections and flare-up of ulcer and cellulitis: 2 case reports
Publicado: (2022)

Contributions of the RAD51 N-terminal domain to BRCA2-RAD51 interaction
por: Subramanyam, Shyamal, et al.
Publicado: (2013)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
por: Zhang, Jingyi, et al.
Publicado: (2022)

Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin
por: Kulsoom, Bibi, et al.
Publicado: (2018)

The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition
por: Mattiello, Luca, et al.
Publicado: (2021)

Thrombotic Microangiopathy with Skin Localization Secondary to Cytarabine-Daunorubicin Association: Report of a Case
por: Regragui, S., et al.
Publicado: (2012)

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Ashok Kumar, Prashanth, et al.
Publicado: (2022)

CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells
por: Qi, Wenxiu, et al.
Publicado: (2014)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

Disseminated Langerhans cell histiocytosis associated with acute myeloid leukaemia: complete remission with daunorubicin and cytarabine
por: Hwang, Yu-Yan, et al.
Publicado: (2012)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

The ATR-Chk1 pathway plays a role in the generation of centrosome aberrations induced by Rad51C dysfunction
por: Katsura, Mari, et al.
Publicado: (2009)

CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling
por: Narayanaswamy, Pavan B, et al.
Publicado: (2016)

Roles of XRCC2, RAD51B and RAD51D in RAD51-Independent SSA Recombination
por: Serra, Heïdi, et al.
Publicado: (2013)

Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor
por: Greenhough, Luke A., et al.
Publicado: (2023)

2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis
por: Jing, Doudou, et al.
Publicado: (2023)

ABCC4 Is a Determinant of Cytarabine‐Induced Cytotoxicity and Myelosuppression
por: Drenberg, CD, et al.
Publicado: (2016)

Homologous Pairing Activities of Two Rice RAD51 Proteins, RAD51A1 and RAD51A2
por: Morozumi, Yuichi, et al.
Publicado: (2013)

Non-Recombinogenic Functions of Rad51, BRCA2, and Rad52 in DNA Damage Tolerance
por: Prado, Félix
Publicado: (2021)

Rad51 paralogs Rad55-Rad57 balance the anti-recombinase Srs2 in Rad51 filament formation
por: Liu, Jie, et al.
Publicado: (2011)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities()
por: Dennis, M., et al.
Publicado: (2013)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
por: Mayer, Lawrence D, et al.
Publicado: (2019)

Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations
por: Gonzalez, R, et al.
Publicado: (1999)

RAD51AP1 mediates RAD51 activity through nucleosome interaction
por: Pires, Elena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hr5tb9rq36j0qmnq7g1shnd4el